GR81710B - - Google Patents

Info

Publication number
GR81710B
GR81710B GR73573A GR840173573A GR81710B GR 81710 B GR81710 B GR 81710B GR 73573 A GR73573 A GR 73573A GR 840173573 A GR840173573 A GR 840173573A GR 81710 B GR81710 B GR 81710B
Authority
GR
Greece
Prior art keywords
amino
alpha
acids
radical
acid
Prior art date
Application number
GR73573A
Other languages
English (en)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of GR81710B publication Critical patent/GR81710B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
GR73573A 1983-01-25 1984-01-23 GR81710B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH39883 1983-01-25

Publications (1)

Publication Number Publication Date
GR81710B true GR81710B (el) 1984-12-12

Family

ID=4186110

Family Applications (1)

Application Number Title Priority Date Filing Date
GR73573A GR81710B (el) 1983-01-25 1984-01-23

Country Status (18)

Country Link
US (1) US4666886A (el)
EP (1) EP0114787B1 (el)
JP (1) JPH068316B2 (el)
AT (1) ATE67769T1 (el)
AU (1) AU569865B2 (el)
CA (1) CA1247089A (el)
DD (1) DD213917A5 (el)
DE (1) DE3485094D1 (el)
DK (1) DK31684A (el)
ES (3) ES8606398A1 (el)
FI (1) FI83524C (el)
GR (1) GR81710B (el)
HU (1) HU192864B (el)
IE (1) IE57092B1 (el)
IL (1) IL70766A (el)
NZ (1) NZ206923A (el)
PT (1) PT78002B (el)
ZA (1) ZA84521B (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004334A1 (en) * 1985-01-18 1986-07-31 MERCK Patent Gesellschaft mit beschränkter Haftung Immunoregulatory peptides
DE3546150A1 (de) 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
CA1315465C (en) * 1987-07-31 1993-03-30 Hans-Helmut Goertz Polymers of oxyalkylated unsaturated quaternary ammonium salts, their preparation and their use
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
DE4119856A1 (de) * 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
ATE147404T1 (de) * 1991-12-19 1997-01-15 Ciba Geigy Ag Aminosulfonsäurederivate und verfahren zu ihrer herstellung
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
EP0604945A1 (en) * 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, its derivatives, production and use thereof
EP0641776A3 (en) * 1993-09-08 1997-05-02 Takeda Chemical Industries Ltd Thioglycerol derivatives.
WO1996040213A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Manufacture and purification of peptides
CA2235245A1 (en) * 1995-10-17 1997-04-24 Dovetail Technologies, Inc Low molecular weight cell, bone marrow and immune stimulants
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
AU2002214127B2 (en) * 2000-10-27 2007-06-07 J. Craig Venter Institute, Inc. Nucleic acids and proteins from streptococcus groups A and B
FR2816060A1 (fr) * 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
AU2006272647A1 (en) * 2005-07-25 2007-02-01 Therimunex Pharmaceuticals, Inc. Peptidyl diacylglycerides
WO2007099650A1 (en) * 2006-03-01 2007-09-07 Fukuoka Prefectural Government Peptide lipid-containing carrier and method for introducing compound into cells using same
US20080051603A1 (en) * 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
KR101080271B1 (ko) * 2009-03-31 2011-11-08 주식회사 웰스킨 다이펩타이드를 유효성분으로 포함하는 자외선에 의한 홍반반응 억제용 화장품 조성물
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
EP3178490B1 (en) 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
DE102009034779A1 (de) * 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
DK2459216T3 (da) 2009-09-02 2013-12-09 Novartis Ag Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EA201390341A1 (ru) 2010-09-01 2013-08-30 Новартис Аг Адсорбция иммунопотенциаторов на нерастворимых солях металлов
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolípidos
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
EP2763695A1 (en) 2011-09-01 2014-08-13 Novartis AG Adjuvanted formulations of staphylococcus aureus antigens
NL2007536C2 (en) * 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
US20150030630A1 (en) 2012-03-07 2015-01-29 Novartis Ag Adjuvanted formulations of rabies virus immunogens
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
RS59971B1 (sr) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals Sa Mutantni stafilokokni antigeni
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
DE102016005550A1 (de) 2016-05-09 2017-11-09 Emc Microcollections Gmbh Adjuvans zur lnduzierung einer zellulären lmmunantwort
WO2018183827A1 (en) * 2017-03-31 2018-10-04 Temple University-Of The Commonwealth System Of Higher Education Flexible variable differential transformer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860893D1 (en) * 1977-06-20 1981-11-05 Ciba Geigy Ag Lipopeptides, process for their preparation and pharmaceutical compositions containing them
HU186585B (en) * 1978-05-18 1985-08-28 Ciba Geigy Ag Process for producing new muramil-peptide derivatives
EP0014815A3 (de) * 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
FR2460290A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux tetra- ou pentapeptides, leur preparation et les medicaments qui les contiennent
FR2460288A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux dipeptides, leur preparation et les medicaments qui les contiennent

Also Published As

Publication number Publication date
IE840157L (en) 1984-07-25
NZ206923A (en) 1988-05-30
ZA84521B (en) 1984-09-26
ES544193A0 (es) 1988-09-16
ES8606398A1 (es) 1986-04-01
PT78002B (en) 1986-06-18
ATE67769T1 (de) 1991-10-15
AU569865B2 (en) 1988-02-25
JPS59139348A (ja) 1984-08-10
ES8606393A1 (es) 1986-04-01
EP0114787B1 (de) 1991-09-25
PT78002A (en) 1984-02-01
ES529091A0 (es) 1986-04-01
HU192864B (en) 1987-07-28
FI83524C (fi) 1991-07-25
EP0114787A2 (de) 1984-08-01
FI83524B (fi) 1991-04-15
ES544194A0 (es) 1986-04-01
DK31684A (da) 1984-07-26
DK31684D0 (da) 1984-01-24
FI840259A0 (fi) 1984-01-23
DD213917A5 (de) 1984-09-26
CA1247089A (en) 1988-12-20
AU2374584A (en) 1984-07-26
JPH068316B2 (ja) 1994-02-02
IE57092B1 (en) 1992-04-22
IL70766A (en) 1987-08-31
FI840259A (fi) 1984-07-26
ES8802620A1 (es) 1988-09-16
US4666886A (en) 1987-05-19
EP0114787A3 (en) 1987-05-06
IL70766A0 (en) 1984-04-30
DE3485094D1 (de) 1991-10-31

Similar Documents

Publication Publication Date Title
GR81710B (el)
ES8606394A1 (es) Procedimiento para la obtencion de tetrapeptidos sustituidos
ES470961A1 (es) Procedimiento para la obtencion de lipopeptidos
ES8501364A1 (es) Un metodo para la preparacion de nuevos polipeptidos.
DE3572491D1 (en) Phosphatidyl compounds, process for their preparation and their use
DK608186A (da) Peptider indeholdende sulfatestergrupper og fremgangsmaade til fremstilling af saadanne peptider
FI904171A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 2'-deoksiuridiinijohdannaisten valmistamiseksi
KR840005733A (ko) 무라밀 펩타이드의 제조방법
IL70160A (en) 6alpha-methylcorticoids,processes for their preparation and pharmaceutical compositions containing them
IL108856A0 (en) Hydroxymethyl-furazancarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
GB1178329A (en) N-[delta-(6-Purinylthio) Valeryl] Amino Acids and derivatives thereof, and a method of producing the same
DE3560262D1 (en) Hexapeptide, process for its preparation and pharmaceutical compositions thereof
ES557260A1 (es) Procedimiento para la obtencion de azacicloalcanos y azacicloalquenos 1,3,4-trisustituidos
AU519719B2 (en) Purification of di peptide
DE3062923D1 (en) Psycho-pharmacological peptides, process for their preparation and therapeutical compositions containing them
SE8302643L (sv) Analoger av neurohypofyshormoner med inhiberande egenskaper
ATE83503T1 (de) Verfahren zur herstellung von l-aminosaeuren.
ES8505939A1 (es) Procedimiento para preparar compuestos que contienen grupos amida de acido carboxilico
AT383811B (de) Verfahren zur herstellung von monoalkalisalzen von 7-amino-3-cephem-4-carbonsaeurederivaten
MX9700929A (es) Metodos y composiciones utiles en la profilaxis y terapia de condiciones relacionadas a la endotoxina.